NCT03805932 2025-07-24
Moxetumomab Pasudotox-tdfk (Lumoxiti(TM)) and Either Rituximab (Rituxan(R)) or Ruxience for Relapsed Hairy Cell Leukemia
National Institutes of Health Clinical Center (CC)
Phase 1 Active not recruiting
Clinical Trials
11 trialsNCT03501615 2020-06-29
MOXE
AstraZeneca
Approved for marketing
NCT01829711 2020-04-08
Moxetumomab Pasudotox for Advanced Hairy Cell Leukemia
MedImmune LLC
Phase 3 Completed
NCT00586924 2019-04-02
A Phase I, Multicenter Dose Escalation Study in Patients With Hairy Cell Leukemia
MedImmune LLC
Phase 1 Completed
NCT01030536 2018-04-09
Safety Study of CAT-8015 to Treat Advanced B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia (NHL or CLL)
MedImmune LLC
Phase 1/2 Completed
NCT00659425 2017-10-02
CAT-8015 in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma
MedImmune LLC
Phase 1 Completed
NCT00587457 2017-07-06
A Phase I, Multicenter, Dose Escalation Study of CAT-8015 in Participants With Chronic Leukemia
MedImmune LLC
Phase 1 Terminated
NCT02338050 2015-09-16
Moxetumomab Pasudotox (CAT-8015, HA22) in Children With B-lineage Acute Lymphoblastic Leukemia and Minimal Residual Disease Prior to Allogeneic Hematopoietic Stem Cell Transplantation
Center for International Blood and Marrow Transplant Research
Phase 2 Terminated
NCT00587015 2011-11-22
A Phase I, Multicenter, Dose Escalation Study of CAT-8015 in Patients With Non-Hodgkin's Lymphoma (NHL)
MedImmune LLC
Phase 1 Terminated
NCT00462189 2007-04-18
Safety Study of CAT-8015 Immunooxin in Patients With HCL With Advance Disease
Cambridge Antibody Technology
Phase 1 Unknown
NCT00457860 2007-04-17
Safety Study of CAT-8015 Immunotoxin in Patients With CLL, PLL or SLL With Advance Disease
Cambridge Antibody Technology
Phase 1 Unknown